Literature DB >> 22486628

The clofibrate saga: a retrospective commentary.

Michael Oliver1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22486628      PMCID： PMC3522803          DOI： 10.1111/j.1365-2125.2012.04282.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  23 in total

1.  The plasma lipids in coronary artery disease.

Authors:  M F OLIVER; G S BOYD
Journal:  Br Heart J       Date:  1953-10

2.  Reduction of serum-lipid and uric-acid levels by an orally active androsterone.

Authors:  M F OLIVER
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

3.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

Authors: 
Journal:  Br Heart J       Date:  1978-10

Review 4.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

5.  Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials.

Authors:  H A Dewar; M F Oliver
Journal:  Br Med J       Date:  1971-12-25

6.  Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.

Authors: 
Journal:  Br Med J       Date:  1971-12-25

7.  WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.

Authors: 
Journal:  Lancet       Date:  1984-09-15       Impact factor: 79.321

8.  FURTHER OBSERVATIONS ON THE EFFECTS OF ATROMID AND OF ETHYL CHLOROPHENOXYISOBUTYRATE ON SERUM LIPID LEVELS.

Authors:  M F OLIVER
Journal:  J Atheroscler Res       Date:  1963 Sep-Dec

Review 9.  Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

Authors:  Jean-Charles Fruchart; Patrick Duriez
Journal:  Drugs Today (Barc)       Date:  2006-01       Impact factor: 2.245

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
View more
  5 in total

Review 1.  Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.

Authors:  Dympna Harmey; Patrick R Griffin; Paul J Kenny
Journal:  Nicotine Tob Res       Date:  2012-09-27       Impact factor: 4.244

2.  Initial Evaluation of Fenofibrate for Efficacy in Aiding Smoking Abstinence.

Authors:  Kenneth A Perkins; Joshua L Karelitz; Valerie C Michael; Margaret Fromuth; Cynthia A Conklin; K N Roy Chengappa; Chris Hope; Caryn Lerman
Journal:  Nicotine Tob Res       Date:  2015-04-20       Impact factor: 4.244

3.  Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.

Authors:  Benjamin Chin-Yee; S V Subramanian; Amol A Verma; Andreas Laupacis; Fahad Razak
Journal:  Milbank Q       Date:  2018-06       Impact factor: 4.911

4.  The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models.

Authors:  Scott P Davies; Courtney J Mycroft-West; Isabel Pagani; Harriet J Hill; Yen-Hsi Chen; Richard Karlsson; Ieva Bagdonaite; Scott E Guimond; Zania Stamataki; Marcelo Andrade De Lima; Jeremy E Turnbull; Zhang Yang; Elisa Vicenzi; Mark A Skidmore; Farhat L Khanim; Alan Richardson
Journal:  Front Pharmacol       Date:  2021-08-06       Impact factor: 5.988

Review 5.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.

Authors:  Shizuya Yamashita; Daisaku Masuda; Yuji Matsuzawa
Journal:  Curr Atheroscler Rep       Date:  2020-01-23       Impact factor: 5.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.